Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Rinaldi

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
The Lancet. Oncology|October 18, 2015
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trialChristophe Tournigand, Benoist Chibaudel, Benoit Samson, et al.
Cancers|June 4, 2020
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal CarcinomaJulie Niogret, Emeric Limagne, Marion Thibaudin, et al.
Clinics and Research in Hepatology and Gastroenterology|June 25, 2020
Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 studyAnthony Turpin, Thierry de Baere, Alexandra Heurgué, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2025
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic CarcinomaMichel Ducreux, Romain Desgrippes, Yves Rinaldi, et al.
Communications Medicine|April 24, 2025
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinomaDavid Tougeron, Christophe Louvet, Jérôme Desramé, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD studyBenoit Rousseau, Marc Hilmi, Antoine Falcoz, et al.
Journal of Geriatric Oncology|April 27, 2020
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLDThomas Aparicio, Ariane Darut-Jouve, Faiza Khemissa Akouz, et al.
The Oncologist|September 5, 2024
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancerEmeric Boisteau, Laetitia Dahan, Nicolas Williet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2024
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER StudyChristelle De La Fouchardière, David Malka, Claire Cropet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 17, 2022
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trialThomas Aparicio, Olivier Bouché, Pierre-Luc Etienne, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
The Lancet. Oncology|October 18, 2015
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trialChristophe Tournigand, Benoist Chibaudel, Benoit Samson, et al.
Cancers|June 4, 2020
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal CarcinomaJulie Niogret, Emeric Limagne, Marion Thibaudin, et al.
Clinics and Research in Hepatology and Gastroenterology|June 25, 2020
Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 studyAnthony Turpin, Thierry de Baere, Alexandra Heurgué, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2025
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic CarcinomaMichel Ducreux, Romain Desgrippes, Yves Rinaldi, et al.
Communications Medicine|April 24, 2025
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinomaDavid Tougeron, Christophe Louvet, Jérôme Desramé, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD studyBenoit Rousseau, Marc Hilmi, Antoine Falcoz, et al.
Journal of Geriatric Oncology|April 27, 2020
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLDThomas Aparicio, Ariane Darut-Jouve, Faiza Khemissa Akouz, et al.
The Oncologist|September 5, 2024
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancerEmeric Boisteau, Laetitia Dahan, Nicolas Williet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2024
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER StudyChristelle De La Fouchardière, David Malka, Claire Cropet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 17, 2022
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trialThomas Aparicio, Olivier Bouché, Pierre-Luc Etienne, et al.
Pageof 3